28 completed. 28 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Completed 28 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Aprepitant: new trials by email Literature Review of Aprepitant trials Research Report on Aprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Bunionectomy HTX-011 Administration Study HTX-011, Luer Lock applicator, Vial access device - Postoperative Pain | Phase 2 | Completed | Heron Therapeutics | 78 | 2018-10-24 | 2026-03-02 |
| Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC Aprepitant - Vomiting, Nausea Post Chemotherapy | Phase 2 | Completed | Chinese Academy of Medical Sciences | 44 | 2018-03-01 | 2020-07-15 |
| A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma Temozolomide, Aprepitant, Minocycline - Glioblastoma | Phase 1 / Phase 2 | Completed | University of Ulm | 10 | 2016-11-01 | 2021-10-05 |
| Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment Aprepitant, Desloratadine, Placebo of aprepitant - Non-small Cell Lung Cancer | Phase 2 | Completed | Sun Yat-sen University | 138 | 2015-12-01 | 2021-05-18 |
| Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries dexamethasone, Gabapentin, Aprepitant - Postoperative Nausea and Vomiting | Phase 2 / Phase 3 | Completed | Assiut University | 150 | 2015-08-01 | 2016-03-24 |
| Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence aprepitant, Placebo, Manual-guided behavioral counseling - Cannabis Dependence, Alcohol Dependence | Phase 2 | Completed | The Scripps Research Institute | 20 | 2014-09-04 | 2017-08-02 |
| Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide aprepitant, ondansetron - Nausea, Vomiting | Phase 2 | Completed | Katy Peters | 136 | 2014-06-24 | 2018-06-26 |
| Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy Olanzapine, Aprepitant - Chemotherapy Induced Nausea and Vomiting | Phase 2 | Completed | Indiana University | 15 | 2014-02-01 | 2017-03-30 |
| Topical Aprepitant in Prurigo Patients Aprepitant, Placebo - Pruritus | Phase 2 | Completed | LEO Pharma | 20 | 2013-10-01 | 2025-03-10 |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas TRC102, CT scan, Lomotil - Lymphomas, Solid Tumors | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 93 | 2013-07-12 | 2024-05-08 |
| Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial Aprepitant, Placebo - Gastroparesis | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 126 | 2013-04-01 | 2019-05-08 |
| A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) Aprepitant, Placebo to Aprepitant, Ondansetron - Post-operative Nausea, Post-operative Vomiting | Phase 2 | Completed | Merck Sharp & Dohme LLC | 229 | 2013-02-12 | 2018-09-25 |
| Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) Fosaprepitant, Fosaprepitant Placebo, Ondansetron - Chemotherapy-induced Nausea and Vomiting | Phase 2 | Completed | Merck Sharp & Dohme LLC | 240 | 2012-12-13 | 2019-06-25 |
| Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy Aprepitant - Acute Myeloid Leukemia | Phase 2 | Completed | University Health Network, Toronto | 41 | 2011-09-01 | 2021-11-22 |
| Treatment for Cannabis Withdrawal and Dependence Aprepitant, Placebo, Manual-guided behavioral counseling - Cannabis Dependence | Phase 2 | Completed | The Scripps Research Institute | 70 | 2011-05-01 | 2017-05-01 |
| Aprepitant in the Management of Biological Therapies-related Severe Pruritus Aprepitant, Prednisone, Fexofenadine - ITCH | Phase 2 | Completed | Campus Bio-Medico University | 45 | 2010-09-01 | 2012-09-12 |
| HBPL Study of the Impact of the NK1 Antagonist Aprepitant Placebo session 1, Aprepitant session 2, Placebo session 1, Placebo session 2 - Cocaine Dependence, Alcohol Dependence | Phase 2 | Completed | University of Pennsylvania | 13 | 2010-09-01 | 2020-07-15 |
| Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin Aprepitant/Ramosetron/Dexamethasone - Chemotherapy-Induced Nausea and Vomiting, Ovarian Cancer | Phase 2 | Completed | Samsung Medical Center | 89 | 2010-05-01 | 2012-10-10 |
| Treatment of Chemotherapy-induced Nausea and Vomiting Aprepitant (Emend), Placebo - Nausea, Vomiting | Phase 2 | Completed | Uppsala University Hospital | 90 | 2010-05-01 | 2012-12-13 |
| Ondansetron Versus Aprepitant Plus Ondansetron for Emesis Ondansetron, Aprepitant - Hematologic Diseases, Acute Myelogenous Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2009-11-01 | 2015-06-25 |
Showing 20 of 28. Sign in to see all of them.
Vomiting (14) · Nausea (12) · Alcoholism (3) · Colonic Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Marijuana Abuse (2) · Neoplasms (2) · Pruritus (2) · Alcohol-Related Disorders (1) · Bile Duct Neoplasms (1) · Bunion (1) · Carcinoma, Non-Small-Cell Lung (1) · Cocaine-Related Disorders (1) · Colorectal Neoplasms (1)
Merck Sharp & Dohme LLC (2) · The Scripps Research Institute (2) · Assiut University (1) · Campus Bio-Medico University (1) · Chinese Academy of Medical Sciences (1) · GlaxoSmithKline (1) · Heron Therapeutics (1) · Indiana University (1) · Katy Peters (1) · LEO Pharma (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1) · OHSU Knight Cancer Institute (1)
United States (15) · China (2) · Germany (2) · Italy (2) · Argentina (1) · Austria (1) · Belgium (1) · Canada (1) · Chile (1) · Croatia (1) · Czechia (1) · Egypt (1) · Hong Kong (1) · Hungary (1) · Japan (1)
Alice P Chen, M.D. (1) · Arthur Blackstock (1) · Barbara J Mason, Ph.D. (1) · Barbara J. Mason, Ph.D. (1) · Daniele Santini, MD, PhD (1) · David T George, M.D. (1) · Duk Soo Bae, MD, PhD (1) · Frank Hamilton, MD, MPH (1) · Gunnar Birgegard, MD, PhD (1) · Hala S Abdel-Ghaffar, MD (1) · Holly Knoderer, MD (1) · Jorge Cortes, MD (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1)
PMID 22995650, PMID 16014882, PMID 16918326, PMID 17085262, PMID 17298105, PMID 17522250, PMID 17535226, PMID 18048820, PMID 18181978, PMID 19692680, PMID 19793151, PMID 20067329, PMID 20493771, PMID 20532044, PMID 20544226, PMID 20718754, PMID 20820812, PMID 21039410, PMID 21630130, PMID 21783417, PMID 22512843, PMID 22850916, PMID 22870909, PMID 24337621, PMID 24517320, PMID 25409596, PMID 28032216, PMID 29111115, PMID 30381138, PMID 30900392, PMID 34620071, PMID 34959641, PMID 36197287, PMID 38396172
R01DA030988 (2), 2009 (1), K01DA025073 (1), U01DK073974 (1), U01DK073975 (1), U01DK073983 (1), U01DK073985 (1), U01DK074007 (1), U01DK074008 (1), U01DK074035 (1)